Back to Newsroom

Global Genomics Group (G3) to Collaborate with Metabolon on Pan-Omic GLOBAL Study to Discover Cardiovascular Disease Biomarkers and Drug Targets

RICHMOND, V.A. and RESEARCH TRIANGLE PARK, N.C., Nov. 14, 2013 – Global Genomics Group (G3) and Metabolon today announced that they have entered into a collaboration agreement to investigate biological networks and pathways in order to discover novel biomarkers and pharmaceutical targets for cardiovascular diseases. Under the terms of the agreement, Metabolon will analyze the biochemicals for the GLOBAL (Genetic LOci and Burden of Atherosclerotic Lesions) study. GLOBAL is the largest pan-omic study combining genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics and lipoprotein proteomics with coronary computed tomographic (CT) angiography, an advanced imaging technology for phenotyping, which allows the precise disease classification in patients.